Published in Oncologist on December 06, 2013
Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica (2015) 0.81
An update on cardio-oncology. Trends Cardiovasc Med (2014) 0.78
Anticoagulation, ferrotoxicity and the future of translational lung cancer research. Transl Lung Cancer Res (2016) 0.75
Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report. Onco Targets Ther (2017) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med (2000) 7.62
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation (2011) 6.47
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation (2007) 5.99
Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation (2007) 5.89
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med (2012) 5.25
Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol (2010) 5.07
Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med (2006) 4.10
Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol (2009) 3.68
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 3.59
Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood (2007) 3.32
Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med (1998) 3.09
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med (2013) 2.84
The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) 2.79
A specific antidote for dabigatran: functional and structural characterization. Blood (2013) 2.77
Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet (2010) 2.65
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost (2012) 2.61
Removal of dabigatran by hemodialysis. Am J Kidney Dis (2012) 2.52
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol (2000) 2.35
Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology (2012) 2.25
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf (2010) 2.13
How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood (2012) 1.91
Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract (2010) 1.80
Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood (2000) 1.73
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2010) 1.71
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol (2011) 1.54
New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet (2013) 1.31
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol (2012) 1.24
Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist (2007) 1.23
Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg (2011) 1.17
In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther (2011) 1.16
The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. Mol Pharm (2011) 1.16
Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer (2010) 1.14
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost (2012) 1.10
New oral anticoagulants in elderly patients. Best Pract Res Clin Haematol (2013) 1.08
Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol (2008) 1.05
The laboratory and the direct oral anticoagulants. Blood (2013) 0.97
Patient time requirements for anticoagulation therapy with warfarin. Med Decis Making (2009) 0.97
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2013) 0.93
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev (2011) 0.89
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Clin Pharmacol (2013) 0.86
Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. J Thromb Haemost (2006) 0.86
Determining the anti-coagulant-independent anti-cancer effects of heparin. Br J Cancer (2010) 0.83
Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly. Drugs Aging (2013) 0.82
Effectiveness of warfarin among patients with cancer. J Gen Intern Med (2007) 0.81
Monitoring target specific anticoagulants. J Thromb Thrombolysis (2013) 0.77
Transportation cost of anticoagulation clinic visits in an urban setting. J Manag Care Pharm (2011) 0.76
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63
The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol (2011) 1.24
Factor XI deficiency and obstetrical anesthesia. Anesth Analg (2009) 1.03
Clinical problem-solving. A bloody mystery. N Engl J Med (2009) 0.81
Case 155: Lane-Hamilton syndrome. Radiology (2010) 0.80
Extended treatment of venous thromboembolism. N Engl J Med (2013) 0.79
Anesthetic management of seven deliveries in three sisters with the May-Hegglin anomaly. Anesth Analg (2009) 0.77
Comparing clinicians' use of an anticoagulation management service and usual care in ambulatory oncology. J Oncol Pharm Pract (2012) 0.77
Prophylaxis against venous thromboembolism in patients with cancer. N Engl J Med (2014) 0.77
Management of inherited thrombophilia in pregnancy. Curr Opin Endocrinol Diabetes Obes (2009) 0.76
Improving anticoagulation management in patients with atrial fibrillation. P T (2013) 0.75
Dabigatran excess: case report and review of the literature. Cardiol Ther (2013) 0.75
Idarucizumab (Praxbind) Formulary Review. Crit Pathw Cardiol (2016) 0.75
Implementation of a Hemostatic and Antithrombotic Stewardship program. J Thromb Thrombolysis (2015) 0.75
Regulatory, legislative, and policy updates with anticoagulant use. J Thromb Thrombolysis (2015) 0.75
Clinical JAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations. Am J Hematol (2008) 0.75
Treating venous thromboembolism in pregnancy. Hematol Oncol Clin North Am (2011) 0.75
Venous thromboembolism overview. Hematol Oncol Clin North Am (2012) 0.75
Interactive medical case. A bloody mystery. N Engl J Med (2009) 0.75